Tag : inflammasome

Cardiology

Cathelicidin aggravates myocardial ischemia/reperfusion injury via activating TLR4 signaling and P2X7R/NLRP3 inflammasome.

Newsemia
Related Articles Cathelicidin aggravates myocardial ischemia/reperfusion injury via activating TLR4 signaling and P2X7R/NLRP3 inflammasome. J Mol Cell Cardiol. 2020 Jan 23;: Authors: Wu Y, Zhang...
Cardiology

MicroRNA-223-3p modulates dendritic cell function and ameliorates experimental autoimmune myocarditis by targeting the NLRP3 inflammasome.

Newsemia
MicroRNA-223-3p modulates dendritic cell function and ameliorates experimental autoimmune myocarditis by targeting the NLRP3 inflammasome. Mol Immunol. 2019 Nov 16;117:73-83 Authors: Chen L, Hou X,...
Gastroenterology

NLRP3 Inflammasome Regulates Development of Systemic Inflammatory Response and Compensatory Anti-inflammatory Response Syndromes in Mice With Acute Pancreatitis

Newsemia
Pancreatitis starts with primarily sterile local inflammation that induces systemic inflammatory response syndrome (SIRS) followed by compensatory anti-inflammatory response syndrome (CARS). We investigated mechanisms of...
Biology

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

Newsemia
by Lieselotte Vande Walle, Irma B. Stowe, Pavel Šácha, Bettina L. Lee, Dieter Demon, Amelie Fossoul, Filip Van Hauwermeiren, Pedro H. V. Saavedra, Petr Šimon,...
Dentistry

Catechin ameliorates Porphyromonas gingivalis-induced inflammation via the regulation of TLR2/4 and inflammasome signaling.

Newsemia
Catechin ameliorates Porphyromonas gingivalis-induced inflammation via the regulation of TLR2/4 and inflammasome signaling. J Periodontol. 2019 Aug 31;: Authors: Lee HA, Song YR, Park MH,...
Pharma / Biotech

Bilirubin alleviates alum-induced peritonitis through inactivation of NLRP3 inflammasome.

Newsemia
Related Articles Bilirubin alleviates alum-induced peritonitis through inactivation of NLRP3 inflammasome. Biomed Pharmacother. 2019 May 20;116:108973 Authors: Lin Y, Wang S, Yang Z, Gao L,...
Latest News

Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept

Newsemia
DUBLIN & CAMBRIDGE, England–(BUSINESS WIRE)–Inflazome, a pioneering inflammasome company developing small molecule drugs that block harmful inflammation, today announces the successful completion of a Series...
Dermatology

Genome editing of human primary keratinocytes by CRISPR/Cas9 reveals an essential role of the NLRP1 inflammasome in UVB sensing.

Newsemia
Related Articles Genome editing of human primary keratinocytes by CRISPR/Cas9 reveals an essential role of the NLRP1 inflammasome in UVB sensing. J Invest Dermatol. 2018...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy